Segment Information - Schedule of Profit and Loss from Segments (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||
| Research and Development Expense [Abstract] | ||||||||
| Manufacturing of preclinical and clinical supplies | $ 13,855 | $ 11,610 | $ 24,647 | $ 16,642 | ||||
| Personnel | 12,809 | 12,001 | 25,199 | 23,366 | ||||
| Clinical trials | 11,430 | 9,070 | 22,434 | 17,581 | ||||
| License of intellectual property | 3,000 | 0 | 3,000 | 0 | ||||
| Development services | 2,178 | 4,197 | 4,534 | 7,765 | ||||
| Other research and development costs | [1] | 1,158 | 760 | 1,969 | 1,302 | |||
| General and administration expenses | 7,591 | 8,268 | 14,534 | 16,386 | ||||
| Interest income | (1,604) | (1,410) | (2,680) | (2,897) | ||||
| Interest expense | 517 | 571 | 1,153 | 865 | ||||
| Other (income) expense, net | 84 | 61 | (257) | 61 | ||||
| Net loss | $ 51,018 | $ 43,515 | $ 45,128 | $ 35,943 | $ 94,533 | $ 81,071 | ||
| ||||||||
| X | ||||||||||
- Definition Clinical Trials No definition available.
|
| X | ||||||||||
- Definition Development Services No definition available.
|
| X | ||||||||||
- Definition License of Intellectual Property No definition available.
|
| X | ||||||||||
- Definition Manufacturing of Preclinical and Clinical Supplies No definition available.
|
| X | ||||||||||
- Definition Personnel Expenses No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. No definition available.
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|